Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Aarti Drugs

₹462.1 4.2 | 0.9%

Market Cap ₹4248 Cr.

Stock P/E 24.8

P/B 3.3

Current Price ₹462.1

Book Value ₹ 139.4

Face Value 10

52W High ₹645

Dividend Yield 0.22%

52W Low ₹ 430

Edit Ratio

Aarti Drugs Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Aarti Drugs Ltd is a pharmaceutical organisation. The Company offers active pharmaceutical ingredients (APIs) in various therapeutic classes, together with anti inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins. Its products beneath APIs consist of Aceclofenac, Diclofenac Potassium, Diclofenac Diethylamine, Clopidogrel Bisulphate and Telmisartan. Its pharma intermediates encompass Antiprotozoal, Celecoxib, Antibiotic, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Zolpidem and Telmisartan. It also gives speciality chemicals, consisting of Benzene Sulphonyl chloride, Methyl Nicotinate, N-Methyl Methane Sulphonamide, Benzene Sulphonamide, Benzene Sulphonic acid methyl ester, Ortho para toluene Sulphonamide, Para Toluene Sulphonic acid methyl ester, Ortho/para toluene Sulphonic acid methyl ester, Para chloro benzene sulphonamide and Para Toluene Sulphonyl Chloride. It's subsidiary is Pinnacle Life Science Pvt Ltd.

Read More..

Aarti Drugs Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Aarti Drugs Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 635 694 622 688 664 742 661 642 606 620
Other Income 7 3 0 0 1 1 1 1 2 1
Total Income 641 697 622 688 665 743 662 642 608 621
Total Expenditure 545 608 555 613 593 649 577 565 536 534
Operating Profit 97 89 67 74 72 94 85 77 72 87
Interest 5 6 7 8 9 9 9 8 8 9
Depreciation 13 13 13 13 13 13 13 13 13 14
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 79 71 48 53 50 73 64 56 52 64
Provision for Tax 20 15 13 14 13 17 16 17 15 17
Profit After Tax 58 55 35 39 37 56 48 40 37 47
Adjustments 0 0 0 0 0 -0 -0 -0 -0 0
Profit After Adjustments 58 55 35 39 37 56 48 40 37 47
Adjusted Earnings Per Share 6.3 6 3.8 4.2 4 6.1 5.2 4.3 4 5.2

Aarti Drugs Profit & Loss

#(Fig in Cr.) Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 501 1097 1140 1195 1244 1561 1806 2155 2489 2716 2529
Other Income 0 1 0 4 1 2 1 5 11 2 5
Total Income 501 1098 1140 1199 1245 1563 1808 2159 2500 2718 2533
Total Expenditure 432 925 960 1005 1042 1350 1541 1714 2156 2407 2212
Operating Profit 69 173 180 194 203 213 267 445 344 312 321
Interest 17 42 48 40 38 44 37 26 24 37 34
Depreciation 19 31 37 38 40 43 49 50 50 50 53
Exceptional Income / Expenses 0 0 0 0 0 4 4 0 0 0 0
Profit Before Tax 33 100 95 116 125 131 185 369 270 224 236
Provision for Tax 10 22 27 34 42 41 44 89 65 58 65
Profit After Tax 24 77 69 82 82 90 141 280 205 166 172
Adjustments 0 0 0 0 0 0 0 0 0 -0 0
Profit After Adjustments 24 77 69 82 82 90 141 280 205 166 172
Adjusted Earnings Per Share 2.5 8 7.1 8.6 8.7 9.5 15.2 30.1 22.1 18 18.7

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 9% 15% 17% 0%
Operating Profit CAGR -9% 5% 9% 0%
PAT CAGR -19% 6% 15% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 2% -17% 25% 25%
ROE Average 15% 24% 23% 22%
ROCE Average 15% 24% 22% 20%

Aarti Drugs Balance Sheet

#(Fig in Cr.) Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 163 308 357 400 455 543 652 913 1036 1192
Minority's Interest 0 0 0 0 0 0 -0 -0 -0 0
Borrowings 267 163 191 202 203 208 180 148 138 205
Other Non-Current Liabilities 23 48 53 95 110 113 121 110 93 91
Total Current Liabilities 70 483 501 494 622 591 623 595 940 933
Total Liabilities 523 1002 1102 1191 1389 1455 1577 1766 2208 2421
Fixed Assets 248 448 493 581 602 625 644 665 690 676
Other Non-Current Assets 16 28 44 39 50 46 29 44 125 253
Total Current Assets 260 526 565 571 737 784 899 1057 1393 1492
Total Assets 523 1002 1102 1191 1389 1455 1577 1766 2208 2421

Aarti Drugs Cash Flow

#(Fig in Cr.) Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 9 5 4 4 3 3 5 7 9 22
Cash Flow from Operating Activities 21 105 133 175 70 143 251 155 70 134
Cash Flow from Investing Activities -76 -107 -99 -107 -74 -62 -33 -72 -150 -164
Cash Flow from Financing Activities 53 1 -33 -68 4 -80 -215 -81 92 17
Net Cash Inflow / Outflow -3 -1 1 -0 0 1 2 2 13 -13
Closing Cash & Cash Equivalent 5 4 5 3 3 5 7 9 22 8

Aarti Drugs Ratios

# Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 2.46 7.98 7.09 8.57 8.73 9.51 15.17 30.09 22.14 17.96
CEPS(Rs) 4.4 11.18 10.87 12.6 12.97 14.03 20.4 35.44 27.54 23.4
DPS(Rs) 0.63 2 1.69 0.25 0.25 0.25 0.5 2.5 1 1
Book NAV/Share(Rs) 16.84 31.81 36.9 41.93 48.28 57.61 70.01 98.01 111.92 128.77
Core EBITDA Margin(%) 13.11 14.58 14.58 14.79 15.99 13.51 14.7 20.44 13.36 11.39
EBIT Margin(%) 9.52 12.01 11.62 12.11 12.9 11.18 12.33 18.34 11.81 9.62
Pre Tax Margin(%) 6.28 8.43 7.73 9.01 9.86 8.39 10.26 17.13 10.85 8.25
PAT Margin (%) 4.46 6.53 5.57 6.35 6.52 5.75 7.83 13.01 8.24 6.12
Cash Profit Margin (%) 8.08 9.16 8.53 9.34 9.69 8.48 10.53 15.33 10.25 7.98
ROA(%) 4.99 10.13 6.53 7.13 6.38 6.31 9.33 16.78 10.32 7.19
ROE(%) 15.18 32.78 20.65 21.6 19.24 17.97 23.65 35.81 21.03 14.93
ROCE(%) 13.12 23.93 17.95 18.14 17.31 17.01 21.39 34.52 20.75 15.49
Receivable days 82.06 67.25 95.59 89.05 97.1 97.45 95.71 88.41 95.71 108.5
Inventory Days 54.05 39.52 50.69 54.97 70.52 61.36 57.8 62.71 69 70.03
Payable days 65.59 58.47 87.3 93.62 112.73 90.28 92.63 95.27 90.28 95.49
PER(x) 6.51 20.43 16.02 16.79 14.52 16.83 8.33 23.09 19.37 18.81
Price/Book(x) 0.95 5.12 3.08 3.43 2.62 2.78 1.81 7.09 3.83 2.62
Dividend Yield(%) 3.91 1.23 1.49 0.17 0.2 0.16 0.4 0.36 0.23 0.3
EV/Net Sales(x) 0.83 1.84 1.39 1.55 1.4 1.29 0.86 3.16 1.8 1.37
EV/Core EBITDA(x) 6.02 11.69 8.78 9.5 8.56 9.43 5.81 15.31 13.05 11.95
Net Sales Growth(%) 4.71 118.92 3.92 4.85 4.05 25.52 15.71 19.31 15.49 9.14
EBIT Growth(%) -23.97 182.71 0.91 8.89 4.38 7.17 27.61 77.47 -25.65 -11.07
PAT Growth(%) -17.35 228.68 -11.04 19.03 0.62 9.05 57.54 98.3 -26.89 -18.85
EPS Growth(%) -15.75 224.5 -11.04 20.82 1.79 9.04 59.45 98.31 -26.41 -18.89
Debt/Equity(x) 1.64 1.45 1.35 1.2 1.2 0.93 0.58 0.38 0.52 0.51
Current Ratio(x) 3.71 1.09 1.13 1.16 1.19 1.33 1.44 1.78 1.48 1.6
Quick Ratio(x) 2.4 0.75 0.77 0.73 0.74 0.91 0.92 1.08 0.92 1.05
Interest Cover(x) 2.93 3.36 2.98 3.9 4.25 4.01 5.95 15.07 12.29 7.04
Total Debt/Mcap(x) 1.73 0.28 0.44 0.35 0.46 0.34 0.32 0.05 0.14 0.19

Aarti Drugs Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 59.99 59.83 59.98 59.77 59.66 59.58 58.7 58.56 57.47 57.13
FII 2.03 2.07 2.07 1.94 1.9 1.94 1.96 2.33 2.1 2.56
DII 2.28 2.69 2.76 3.16 3.9 4.09 4.71 5.32 5.26 5.99
Public 35.71 35.41 35.19 35.13 34.54 34.39 34.62 33.79 35.17 34.32
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 24%

Cons

  • Debtor days have increased from 90.28 to 95.49days.
  • Stock is trading at 3.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Aarti Drugs News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!